As of November 8, 2026, 9 holders' latest Schedule 13D or 13G filings report owning 5% or more of Crescent Biopharma Inc. The largest reported stake is Fairmount Funds Management LLC's, at 16.52%. 16 filings are on record since July 8, 2025 (Schedule 13D/A, July 20, 2026).
Sell to companies like Crescent Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 2,034,925 · Shared voting: 0 · Sole dispositive: 2,075,291 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: Balyasny Asset Management L.P. · Sole voting: 1,662,917 · Shared voting: 0 · Sole dispositive: 1,662,917 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Fairmount Funds Management LLC · Sole voting: 0 · Shared voting: 6,593,385 · Sole dispositive: 0 · Shared dispositive: 6,593,385 · SCHEDULE 13D/A, 2026-07-20
- · Holder: Balyasny Asset Management L.P. · Percent: 5.48% · SCHEDULE 13G
- · Holder: Tang Capital Management, LLC · Percent: 4.21% · SCHEDULE 13G/A
Crescent Biopharma Inc has 16 Schedule 13D or 13G filings on record since 2025-07-08. 9 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 16.52% | 6,593,385 | SCHEDULE 13D/A, 2026-07-20 | 2026-07-16 |
| Fmr LLC | 15% | 4,133,514 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| 1Globe Capital LLC | 10.3% | 1,425,432 | SCHEDULE 13G/A, 2025-10-14 | 2025-10-07 |
| Bvf Partners L P | 9.99% | 1,387,863 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Venrock Healthcare Capital Partners III, L.P. | 9.5% | 2,666,064 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| ForGrowth III PA B.V. | 6.1% | 1,677,852 | SCHEDULE 13G, 2025-12-11 | 2025-12-08 |
| Balyasny Asset Management L.P. | 6.03% | 1,662,917 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 5.6% | 2,075,291 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Vestal Point Capital, LP | 5.4% | 1,500,000 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Tang Capital Management, LLC | 4.21% | 1,160,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Logos Global Management LP | 4.1% | 575,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Crescent Biopharma Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Crescent Biopharma Inc and the records around it.
Crescent Biopharma Inc elsewhere on the record
Companies that share a holder
- 1Globe Capital LLC also filed stake reports on 1 other company: SINOVAC BIOTECH LTD (Sep 2025)
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Vor Biopharma Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
Watch Crescent Biopharma Inc
Get an email when Crescent Biopharma Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Crescent Biopharma Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Crescent Biopharma Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Crescent Biopharma Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 0 | 6,593,385 | 0 | 6,593,385 | SCHEDULE 13D/A, 2026-07-20 |
| Fairmount Healthcare Fund II L.P. | 0 | 6,593,385 | 0 | 6,593,385 | SCHEDULE 13D/A, 2026-07-20 |
| Peter Harwin | 9,023 | 6,593,385 | 9,023 | 6,593,385 | SCHEDULE 13D/A, 2026-07-20 |
| Tomas Kiselak | 0 | 6,593,385 | 0 | 6,593,385 | SCHEDULE 13D/A, 2026-07-20 |
| Balyasny Asset Management L.P. | 1,662,917 | 0 | 1,662,917 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Bam Gp LLC | 1,662,917 | 0 | 1,662,917 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Balyasny Asset Management Holdings LP | 1,662,917 | 0 | 1,662,917 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dames GP LLC | 1,662,917 | 0 | 1,662,917 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dmitry Balyasny | 1,662,917 | 0 | 1,662,917 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 2,034,925 | 0 | 2,075,291 | 0 | SCHEDULE 13G, 2026-10-27 |
The latest filing identifies Crescent Biopharma Inc by CUSIP G2545C104 and gives its principal executive office as 300 FIFTH AVENUE, Waltham, MA 02451 (SCHEDULE 13G, 2026-10-27).
What the percentages are based on
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 6.03% of the Shares, based on 27,571,935 7 Shares of class A common stock outstanding as of April 24, 2026 as reported in the Issuer's Quarterly Report on Form 10-Q/A as filed with the Securities Exchange Commision on June 22, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14
Purpose of Transaction (Item 4)
Fairmount Funds Management LLC
Item 4 of the Statement is hereby amended and supplemented as follows: Fund II purchased the Ordinary Shares and Pre-funded Warrants referenced in Item 3 for investment purposes. Lock-Up Agreement In connection with the Company's underwritten public offering of Ordinary Shares and Pre-Funded Warrants that closed on July 16, 2026, the Reporting Persons entered into a customary lock-up letter agreement (the "Lock-Up Agreement") with Jefferies LLC and TD Securities (USA) LLC acting as the Representatives (collectively, the "Representatives") of the underwiters party to to an underwriting agreement with the Company. Pursuant to the Lock-Up Agreement, the Reporting Persons agreed to refrain from selling shares of the Company's securities without the consent of the Representatives, and other customary lock-up conditions, for a period of 60 days following the date of the final prospectus supplement for the offering. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the Form of Lock-Up Agreement, which is filed as Exhibit 99.2 to this Schedule 13D and incorporated herein by reference. Pre-Funded Warrants The Pre-Funded Warrants purchased by Fund II in the offering have an exercise price of $0.001, are immediately exercisable at any time after the date of issuance and will not expire. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-08 | Fmr LLC | 10.2% | SCHEDULE 13G |
| 2025-08-14 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2025-08-14 | Logos Global Management LP | 4.1% | SCHEDULE 13G/A |
| 2025-08-20 | 1Globe Capital LLC | 6.45% | SCHEDULE 13G |
| 2025-10-09 | Tang Capital Management, LLC | 5.04% | SCHEDULE 13G |
| 2025-10-14 | 1Globe Capital LLC | 10.3% | SCHEDULE 13G/A |
| 2025-12-08 | Fairmount Funds Management LLC | 18.53% | SCHEDULE 13D/A |
| 2025-12-11 | ForGrowth III PA B.V. | 6.1% | SCHEDULE 13G |
| 2026-02-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2026-02-17 | Vestal Point Capital, LP | 5.4% | SCHEDULE 13G |
| 2026-02-17 | Venrock Healthcare Capital Partners III, L.P. | 9.5% | SCHEDULE 13G/A |
| 2026-05-15 | Balyasny Asset Management L.P. | 5.48% | SCHEDULE 13G |
| 2026-05-15 | Tang Capital Management, LLC | 4.21% | SCHEDULE 13G/A |
| 2026-07-20 | Fairmount Funds Management LLC | 16.52% | SCHEDULE 13D/A |
| 2026-08-14 | Balyasny Asset Management L.P. | 6.03% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 5.6% | SCHEDULE 13G |
Questions about who owns Crescent Biopharma Inc
Who owns Crescent Biopharma Inc?
On this page, 9 holders' latest ownership filings report 5% or more of Crescent Biopharma Inc: Fairmount Funds Management LLC (16.52%, Schedule 13D/A, filed 2026-07-20), Fmr LLC (15%, Schedule 13G/A, filed 2026-02-05), 1Globe Capital LLC (10.3%, Schedule 13G/A, filed 2025-10-14), Bvf Partners L P (9.99%, Schedule 13G/A, filed 2025-08-14) and Venrock Healthcare Capital Partners III, L.P. (9.5%, Schedule 13G/A, filed 2026-02-17); 4 more are listed above.
Who are the largest shareholders of Crescent Biopharma Inc?
By the share each holder's latest filing reports, the largest holders of Crescent Biopharma Inc on this page are Fairmount Funds Management LLC (16.52%), Fmr LLC (15%) and 1Globe Capital LLC (10.3%).
When did Fairmount Funds Management LLC buy into Crescent Biopharma Inc?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2025-12-08, reporting 18.53%; its latest, Schedule 13D/A filed 2026-07-20, reports 16.52%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Crescent Biopharma Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.